Physician profile
Sarah Driscoll
NPI 1326605031
$5,372.32
in general payments reported to CMS, 2019-2025
18 companies · $485 in 2025
The $485 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.67 · 2020: $101 · 2021: $236 · 2022: $933 · 2023: $2,757 · 2024: $774 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513 · Travel and Lodging: $1,504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.73 |
| Travel and Lodging | $1,503.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,486.29 | 2020-2025 | Dailies Aqua Comfort Plus, Air Optix, Dailies Total1 Multifocal |
| Coopervision INC. | $889.20 | 2022-2025 | Misight Contact Lens |
| Bausch & Lomb Americas INC. | $739.90 | 2023-2025 | Infuse, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $192.09 | 2022-2023 | Cequa |
| Horizon Therapeutics Plc | $187.90 | 2021-2023 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $182.02 | 2020-2024 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $136.42 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $134.40 | 2023-2025 | Acthar |
| Amgen INC. | $101.89 | 2024 | Tepezza |
| Carl Zeiss Meditec, INC. | $86.67 | 2019 | |
| Dompe US, INC. | $55.54 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $42.31 | 2022-2025 | |
| Abbvie INC. | $42.04 | 2023 | Durysta |
| Genentech USA, INC. | $26.30 | 2025 | Vabysmo |
| Rxsight INC | $21.01 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $19.35 | 2024 | Vevye |
| Alimera Sciences, INC. | $15.25 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Driscoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.